Report Highlights

Neurorehabilitation Gaming Systems in the U.S.: Market Overview

The U.S. neurorehabilitation gaming systems market was valued at USD 385.4 million in 2024 and is forecast to reach USD 1,046.2 million by 2032. The market spans robotic upper-limb trainers, sensor-based motion platforms, and FDA-authorised virtual reality therapy applications used in stroke, traumatic brain injury, and multiple sclerosis care. Device clearance sits with the FDA's Center for Devices and Radiological Health, while Medicare reimbursement is set by the Centers for Medicare and Medicaid Services.

Government has been the dominant force in shaping demand rather than supply. The Department of Veterans Affairs, through its Rehabilitation Research and Development Service, funded early trials of gaming-based rehabilitation for veterans with traumatic brain injury. Private firms, including Motek Medical and Applied VR, have led product development, while the 21st Century Cures Act of 2016 narrowed FDA oversight of certain non-device health software and encouraged venture investment in digital therapeutics.

Policy-Driven Growth in U.S. Neurorehabilitation Gaming

Three mechanisms drive demand. First, Medicare Part B covers outpatient therapy under 42 CFR Part 410, and clinics bill therapeutic activities such as CPT 97530 when delivering gaming-based sessions, so each covered session converts directly into clinic revenue. Second, the CMS Transitional Coverage for Emerging Technologies pathway, finalised in August 2024, provides coverage with evidence development for up to five breakthrough technologies annually, accelerating reimbursement for FDA Breakthrough-designated rehabilitation systems.

Third, the National Institute on Disability, Independent Living, and Rehabilitation Research funds Rehabilitation Engineering Research Centers, while NIH SBIR Phase II awards, typically up to USD 2 million in direct costs, underwrite early commercialisation. These grants reduce validation costs and generate peer-reviewed outcome evidence, which CMS and commercial payers require before covering new therapy modalities.

Regulatory Barriers and Compliance Costs

Most neurorehabilitation gaming systems are classified as Class II devices under 21 CFR 890.5 and require 510(k) premarket notification. The MDUFA performance goal for 510(k) review is 90 FDA days, but total elapsed time commonly reaches 6 to 12 months once deficiency responses are included. Software-only platforms with novel claims face De Novo classification, where the goal is 150 FDA days and annual user fees under the Medical Device User Fee Amendments apply.

Data and billing rules add further cost. Gaming systems recording patient performance data must comply with the HIPAA Security Rule, enforced by the HHS Office for Civil Rights. Clinics billing Medicare must document medical necessity under local coverage determinations issued by Medicare Administrative Contractors, and this documentation adds several staff hours per patient episode that clinics weigh against device adoption.

Policy-Created Opportunities in the U.S.

The MISSION Act of 2018 expanded Veterans Affairs Community Care eligibility, allowing veterans to access private neurorehabilitation providers. Clinics equipped with FDA-authorised gaming systems can therefore receive VA-funded referrals for traumatic brain injury and limb loss, creating a funded demand pool that operates independently of Medicare utilisation rules.

Medicare's Remote Therapeutic Monitoring codes, CPT 98975 through 98986, introduced in the CY 2022 Physician Fee Schedule, create billable home-based motion data collection. RTM covers only musculoskeletal and respiratory conditions, so stroke-related upper-limb programmes require musculoskeletal coding strategies, an opportunity for vendors offering validated diagnosis-mapping documentation.

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, as amended by the Medical Device Amendments of 1976, the Medical Device User Fee Amendments, and the 21st Century Cures Act of 2016. The FDA's Center for Devices and Radiological Health administers premarket review. Section 524B of the FD&C Act, added by the Food and Drug Omnibus Reform Act of 2022, requires cybersecurity plans, software bills of materials, and vulnerability management for connected devices, which applies directly to networked gaming platforms.

Upcoming changes are scheduled. The FDA Quality Management System Regulation takes effect on February 2, 2026, aligning U.S. requirements with ISO 13485. Compared with regional peers, the U.S. framework is faster to market than the EU Medical Device Regulation (EU) 2017/745, which requires notified body involvement for most Class IIa devices. However, Health Canada's Medical Devices Regulations (SOR/98-282) impose comparable quality system obligations, narrowing the cost gap between markets.

Long-Term Policy Outlook for Neurorehabilitation Gaming in the U.S.

By 2032, the QMSR will be fully embedded in manufacturer quality systems, raising compliance costs for smaller hardware makers while favouring established suppliers. CMS will continue issuing annual Physician Fee Schedule updates, and each update will determine whether gaming-based therapy codes migrate from Category III to permanent status, which directly sets the revenue timeline for vendors.

Reimbursement will shift toward outcome-based payment as TCET evidence accumulates across breakthrough devices. Cybersecurity requirements under Section 524B will become a procurement condition for VA and hospital buyers. Vendors holding documented cybersecurity plans and CMS-recognised outcome data will secure long-term contracts, while those lacking them will lose access to federal and hospital channels.

Market Segmentation